trending Market Intelligence /marketintelligence/en/news-insights/trending/pyhl6862skmsbsovpq2bxa2 content esgSubNav
In This List

Gilead Sciences licenses California-based company's drug discovery technology

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Gilead Sciences licenses California-based company's drug discovery technology

Gilead Sciences Inc. said it entered a license agreement with San Francisco-based Trianni Inc. to use its drug discovery platform.

The financial details of the agreement were not disclosed in a Sept. 4 news release.

Trianni's transgenic human monoclonal antibody discovery platform uses genetically engineered mice to generate antibodies that can be effective in humans.